Conference - Events

LNPs continue to dominate the spotlight in biopharma with three landmark acquisitions in the past six months, AbbVie/Capstan Therapeutics, Eli Lilly and Co/Verve Therapeutics and Bristol Myers Squibb/Orbital Therapeutics. Validating LNPs as a stand-out delivery vehicle for cell and gene therapies! Returning to Boston in April 2026, the 5th LNP Formulation and Process Development Summit is an industry-led end-to-end meeting providing the latest scientific content to advance LNP development for a variety of payloads and therapeutic applications, from mRNA vaccines to next-generation cell and gene therapies. This is your one-stop shop to hear insights on LNP discovery, analytics, formulation, process development and large-scale manufacturing. With 3 focused streams, Analytical Development and…

EDUCATION IS OUR TOP PRIORITY!With education documentation becoming a way of life and the budget constraints facing many hospitals and institutions, in conjunction with the Society of Interventional Radiology (SIR) and the Association for Radiologic and Imaging Nursing (ARIN), AVIR strives to build an education program that meets and exceeds the expectations of our attendees. The AVIR Annual Scientific Meeting continues to provide an excellent venue for participation and marketing for our corporate sponsors. AVIR MISSIONis to grow, advance, and continue education in the area of vascular and interventional radiology and to promote professional growth and resources for AVIR members throughout the medical community.The AVIR is comprised of department managers, chief technologists, directors a…

Neuroimmunology is entering a defining moment. With the $470M buyout of Vigil’s TREM2 asset, Ventus’ NLRP3 inhibitor in phase 2a, and promising phase 3 BTKi readouts from Sanofi and Roche, the field is beginning to show encouraging signs of clinical viability in targeting neuroinflammation. Now the real race begins. Uncovering the next wave of mechanisms, biomarkers, and translational strategies that will move beyond today’s successes and unlock new therapeutic frontiers in neurodegeneration and neuroimmune-driven psychiatric disease. The 8th Neuroimmunology Drug Development Summit is the industry’s only meeting fully dedicated to advancing novel neuroinflammatory targets, uniquely bridging cutting-edge academic discovery with the practical lens of drug development. This year’s expanded pr…

Thought Leader Texas is a premier gathering for executives, innovators, and industry leaders who want to stay ahead of fast-moving shifts in business, leadership, and organizational strategy. This summit brings together experts from across sectors to share fresh perspectives, practical insights, and proven approaches that help leaders navigate today’s most pressing challenges. Through keynote talks, panel discussions, and interactive sessions, attendees will explore themes such as leadership development, talent and culture, operational excellence, technology adoption, and long-term strategic growth. Each session is designed to offer actionable takeaways-clear ideas and tools executives can bring back to their organizations. The event also creates space for meaningful networking, allowing l…

Europe's oligonucleotide landscape is entering a pivotal growth phase. With the €21M launch of Aerska and major collaborations such as Novartis and SciNeuron, Lundbeck and Contera, and Secarna and Vect-Horus, European biopharma are rapidly advancing RNA-targeted approaches to address previously undruggable CNS diseases.  In response to this momentum, the inaugural Oligonucleotides for CNS Summit Europe will unite 60+ senior industry leaders for the first European forum dedicated exclusively to CNS-focused Oligonucleotide therapeutics.  The summit delivers three days of highly technical, data-driven discussions addressing the challenges unique to CNS development with insight into next-generation BBB delivery strategies beyond TfR1, advanced in vivo and iPSC models, novel chemistry…

The Marcus Evans 17th Edition Strategic Alliance Management for Pharma conference taking place in Barcelona, Spain on 21-23 April, 2026, will explore how to build resilient partnerships that deliver measurable value, leveraging both human and AI-driven capabilities. It will bring together leading pharma and biotech companies to discuss how alliances are evolving across the full partnership lifecycle - from deal negotiation to execution, governance, and value creation. It wll focus as well on the rapidly evolving environment shaped by AI adoption, global market shifts, cultural dynamics, and new partnership models. Attending this premier Marcus Evans conference will enable you to: Establish Effective Governance and Decision-making Process within the Alliance Navigating Data Management from…

The Marcus Evans 17th Edition Strategic Alliance Management for Pharma conference taking place in Barcelona, Spain on 21-23 April, 2026, will explore how to build resilient partnerships that deliver measurable value, leveraging both human and AI-driven capabilities. It will bring together leading pharma and biotech companies to discuss how alliances are evolving across the full partnership lifecycle - from deal negotiation to execution, governance, and value creation. It wll focus as well on the rapidly evolving environment shaped by AI adoption, global market shifts, cultural dynamics, and new partnership models. Attending this premier Marcus Evans conference will enable you to: Establish Effective Governance and Decision-making Process within the Alliance Navigating Data Management from…

One foundation. Cross-functional strength. Elevated impact. For years, the question was: What do we build next? More sophisticated AI. More advanced engagement models. Wider access strategies. Each impressive. Each reaching higher. Then market winds shifted. New regulations arrived. Suddenly, the question changed: Can our foundations hold? Walls between functions preventing flexibility. Disconnected data infrastructure fragmenting insights. Inefficiencies becoming liabilities under pressure. Those walls aren't load-bearing, they're removable. That data infrastructure can reinforce decisions. And patient purpose? That's the force binding everything together. You must underpin your customer engagement strategy with reimagined data and infrastructure. You must reprioritise your launch plans t…

The conference features a comprehensive pre-conference focus day dedicated to advancements in device design, followed by a dynamic two-day main conference featuring keynote plenaries, interactive panel discussions, and specialized topic streams covering the most pressing industry challenges and breakthrough solutions including: Device Innovations for Large Volume and Novel Drug Product DeliveryAdvancing Sustainability in the Injectable Device IndustryPrimary Packaging: Ensuring Safe, Stable, and Biocompatible Combination ProductsPatient-Driven Device Design Date and Time: Monday, 27 April 2026 at 08:30 - Wednesday, 29 April 2026 at 17:00

The BPG 2026 will be organised in Blankenberge on April 27-28 for the 2026 edition of the Annual Meeting of the Belgian Polymer Group! The 2026 edition will provide a platform to discuss all current topics in polymer science, engaging both industrial and academic perspectives. The event will also be an opportunity for young Belgian scientists specialising in polymers to present their work through oral communications and posters. The programme will be enriched by invited lectures. At a broader level, the aim of the Belgian Polymer Group (BPG) is to encourage links between the key players in the field of polymer science, both in industry and academia. The BPG also seeks to monitor current research directions being pursued at various universities and industrial R&D laboratories in Belgium…

From transformative genetic therapies in rare diseases to neuroimmunology candidates addressing residual unmet needs in MS, and novel target validation driving confidence in disease modification for neurodegeneration, best- and first-in-class neuroscience opportunities continue to shape and drive pharma investment. Returning for its second year, following the inaugural launch that attracted over 100 attendees, the 2nd Neuroscience Innovation Partnering and Licensing Summit is strategically timed to facilitate multiple high-impact, in-person meetings without the distractions of a broader, less focused setting. Who Attends This Differentiated Business Development Initiative? - Global Pharma: Heads of Business Development, Search and Evaluation, and Asset Scouting for Neuroscience - comparing…

Optimizing ADC Physiochemical, Potency, and Impurity Analytical Methods to Enhance Product Understanding, Quality and Assess DARs for Regulatory Submissions The 5th ADC Analytical Development Summit is the only dedicated platform for tackling the unique analytical complexities of ADC development, bringing together technical leaders to ensure a high-quality, regulatory-compliant ADC product. The ADC landscape is undergoing a rapid transformation with novel modalities like bispecifics, dual payload conjugates, and novel conjugates all push the boundaries of innovation, whilst more traditional ADCs are progressing their way through the pipelines - analytical teams are facing greater challenges in ensuring product quality and regulatory compliance than ever. The 5th ADC Analytical Development…

The GPCR field is experiencing a renaissance, driven by renewed investment, clinical progress, and next-generation technologies unlocking hundreds of previously untargeted receptors. With rapid advances in structural biology, computation, and screening, the race is on to validate new GPCRs, understand dynamic activation mechanisms, and develop assays that better predict therapeutic efficacy and guide smarter candidate selection. Returning as the only industry-led meeting dedicated to GPCR drug discovery, the 5th GPCR-Targeted Drug Discovery Summit features a jam-packed agenda featuring new expert voices, and fresh insights spanning the latest targets, tools, and therapeutic strategies. Join 80+ GPCR-focused leaders across biopharma to share insights, build collaborations, and accelerate ne…

Peptide therapies are rapidly becoming a disruptive modality, led by Merck’s oral PCSK9 inhibitor and Johnson and Johnson’s IL23R, with the hope to develop best-in-class drugs with improved chemistry, formulation and clinical efficacy. To shine a light on the progress of this field, the highly anticipated 3rd Peptide-Based Therapeutics Summit returns to Boston as the industry’s only dedicated platform to turbocharge the next generation of peptide discoveries through development and towards life-saving treatments. Gathering industry leaders including Parabilis Medicines, Circle Pharma, Abbvie, Merck, Chugai Pharmaceuticals and many more, this is your premium forum to explore: - Novel computational tools- Optimize analytical assays- Formulating cell-specific delivery methods- DMPK translatab…

AI is transforming every corner of drug discovery, and biophysics is no exception. From predicting molecular interactions to streamlining data analysis with machine learning, AI is enabling faster, more informed early-stage decisions. Meanwhile, experimental biophysics continues to evolve, with high-resolution and high-throughput platforms expanding the boundaries of what can be measured. Techniques like focal molography, alongside innovations in membrane mimetics and nanodiscs, are providing unprecedented insight into complex targets, including previously intractable membrane proteins. As targets grow more complex and modalities more diverse, the demand for accurate biophysical understanding has never been more essential. From prioritizing hits and defining on-target engagement to optimiz…

Regulatory and governmental momentum is forcing change, fast: The Senate have recently cleared the FDA Modernization Act 3.0The FDA have developed a roadmap that’s abandoning animal testing for mAbsNIH have closed the door on animal-only grantsThe UK join the plan to phase out animal testing, announced by the Science Minster Lord Vallance Meanwhile, your pipelines are chasing novel targets that in vivo models can't predict. The 11th 3D Tissue Models Summit is where the industry comes to solve this. As the only industry-led forum dedicated to advancing organoids, organ-on-chip, and MPS, you'll connect with scientists from AbbVie, Novartis, Vertex, and many more who are validating these models, securing regulatory buy-in, and making them work at scale. The shift is happening, so make sure yo…

The Pharma Partnering Summit is an exclusive Life Sciences Industry event, with the aim to help companies expand their network and put together licensing deals, research collaborations and financing. Our platform brings together senior executives from different parts of the world specialising in Business Development & Licensing, Alliance Management, Research Collaborations, M&A and Investment. In addition to identifying products and partners as well as investors, the forum also serves to disseminate knowledge through expert speakers, for the best practices in the field of industry partnerships.  

The pharmaceutical industry is poised for a paradigm shift: moving away from animal models prior to human trials. This conference unites leaders from pharma, academia, and the exhibitor ecosystem to address the critical question: What is needed to engineer the post-animal drug discovery pipeline? Achieving this future requires fundamental changes – testing compounds earlier in more relevant cells, at significantly larger scales, to generate the comprehensive foundational data necessary to reduce animal dependency. Our 4 structured sessions will tackle the core transitions we need to make to achieve this future state. Relevant biology at scale will explore innovations in complex in vitro models and showcase where we are already having success. Redesign of assay and data pipelines will addre…

Attend the Marcus Evans 21st Edition Project Portfolio and Resource Management Excellence for Pharma and BioTech conference taking place in New Jersey between 7-8 May and explore how leading pharma and biotech organizations are strengthening portfolio decision-making frameworks amid rising regulatory pressures, investment constraints, and scientific uncertainty. This event will examine evolving expectations around governance discipline, cross-functional alignment and evidence-based valuation, alongside how teams are embedding advanced analytics and AI to enhance forecasting, scenario modelling and risk assessment. Sessions will also address the operational realities of resource bottlenecks, shifting strategic priorities and accelerated development timelines, while senior leaders share best…